The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004

• Citation: S.I. 2004/2693
• Sections: 6

Section 1 Citation, commencement and interpretation

(1) This Order may be cited as the Prescription Only Medicines (Human Use) Amendment (No.3) Order 2004 and shall come into force on 19th November 2004.

(2) In this Order, “the principal Order ” means the Prescription Only Medicines (Human Use) Order 1997 .

Section 2 Amendment of article 1 of the principal Order

In article 1 of the principal Order (interpretation), in paragraph (2), after the definition of “inhaler” insert the following definition—

“Local Health Board” has the same meaning as in the National Health Service Act 1977 ;

Section 3 Amendment of article 7 of the principal Order

In article 7 of the principal Order (exemption for parenteral administration in an emergency to human beings of certain prescription only medicines), in the list insert, in the appropriate alphabetical place, each of the following entries—

“Atropine sulphate and obidoxime chloride injection”;

“Atropine sulphate and pralidoxime chloride injection”;

“Atropine sulphate, pralidoxime mesilate and avizafone injection”;

“Pralidoxime chloride injection”; and

“Pralidoxime mesilate injection”.

Section 4 Insertion of article 7A of the principal Order

After article 7 of the principal Order, insert the following article—

Exemptions for administration of smallpox vaccine

(7A)

(1) The restriction imposed by section 58(2)(b) (restriction on administration) shall not apply to the administration to human beings of smallpox vaccine where the conditions specified in paragraph (2) or (3) are satisfied.

(2) The conditions referred to in this paragraph are—

(a) the vaccine has been supplied by, or on behalf of, or under arrangements made by—

(i) the Secretary of State,

(ii) the Scottish Ministers,

(iii) the National Assembly for Wales,

(iv) the Department of Health, Social Services and Public Safety,

(v) an NHS body; and

(b) the vaccine is administered for the purpose of providing protection against smallpox virus in the event of a suspected or confirmed case of smallpox in the United Kingdom.

(3) The conditions referred to in this paragraph are—

(a) the vaccine has been supplied by, or on behalf of, or under arrangements made by Her Majesty’s Forces;

(b) the vaccine is administered for the purpose of providing protection against smallpox virus to—

(i) members of Her Majesty’s Forces; or

(ii) other persons employed or engaged by those Forces.

(4) For the purposes of this regulation, “NHS body” means—

(a) the Common Services Agency,

(b) a Strategic Health Authority, Health Authority or Special Health Authority,

(c) a Primary Care Trust,

(d) a Local Health Board, or

(e) an NHS trust or NHS foundation trust

Section 5 Amendment of Schedule 3A to the principal Order

In the table in Schedule 3A to the principal Order (substances which may be prescribed, administered or directed for administration by extended formulary nurse prescribers and conditions for such prescription or administration)—

(a) in the entry for “Amitriptyline Hydrochloride”, in column 2, after “Oral” insert “administration in palliative care”;

(b) in the entry for “Carbamazepine”, in column 2, after “Oral or rectal” insert “administration in palliative care”;

(c) in the entry for “Gabapentin”, in column 2, after “Oral” insert “administration in palliative care”;

(d) in the entry for “Imipramine hydrochloride”, in column 2, after “Oral” insert “administration in palliative care”; and

(e) in the entry for “Nortriptyline hydrochloride”, in column 2, after “Oral” insert “administration in palliative care”.

Section 6 Amendment of Schedule 5 to the principal Order

In Schedule 5 to the principal Order (exemption for certain persons from section 58(2) of the Medicines Act 1968), in paragraph 9 of Part III, in column 2, in sub-paragraph (c), after the entry for “Adrenaline Acid Tartrate” insert the following entry—

“Amiodarone”.